ATSE 2017 New Fellow: Professor Mark Kendall FTSE

December 5, 2017
Professor Kendall, a biomedical engineer, has been central to the development of the Nanopatch, which potentially will revolutionise global vaccination. He conceived and patented the technology that distinguishes the Nanopatch from other intradermal delivery devices, led the research program to take it to proof-of-concept in the animal model, founded Vaxxas to take the Nanopatch into the clinic as a commercial product, led the R&D program and secured partnerships with Merck and the World Health Organisation for specific product development. The Nanopatch is seen as a potential game-changer for vaccine delivery and vaccine innovation.
Previous Video
ATSE 2017 New Fellow: Professor Linda Kristjanson AO FTSE
ATSE 2017 New Fellow: Professor Linda Kristjanson AO FTSE

Professor Kristjanson is the inspiring leader of Swinburne University of Technology. She has developed, and...

Next Video
ATSE 2017 New Fellow: Dr Kourosh Kayvani FTSE
ATSE 2017 New Fellow: Dr Kourosh Kayvani FTSE

Dr Kayvani has played key engineering roles in many award-winning projects across the globe over 28 years. ...